Sanofi-Aventis has taken out full-page ads in major US newspapers to defend the safety of its insomnia drug Ambien (zolpidem tartrate), following negative publicity about reports that some patients could not recall driving or eating while sleepwalking when using the hypnotic. It says that the events are rare and that, when taken as prescribed, the sleep aid is safe and effective.The move follows a civil suit filed on March 6th, alleging that the company failed to give patients adequate warning of the risk of sleepwalking and sleep eating associated with the use of Ambien (Scrip No 3140, p 14). The company denies any allegation of negligence because the US data sheet warns of the potential rare effect of somnambulism (sleepwalking).
展开▼
机译：赛诺菲-安万特（Sanofi-Aventis）已在美国主要报纸上刊登整版广告，以捍卫其失眠药Ambien（酒石酸zolpidem酒石酸盐）的安全性，此前有报道称一些患者在使用催眠药时梦游时不记得开车或进食，因此遭到负面宣传。它说事件很少见，按规定服用，助眠药是安全有效的。此举是在3月6日提起民事诉讼之后提出的，该公司称该公司未能向患者提供充分的梦游风险警告。睡眠饮食与使用Ambien有关（Scrip No 3140，p 14）。该公司否认有任何过失指控，因为美国数据表警告说梦游症（梦游）的潜在罕见影响。
展开▼
